Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000 common shares offered by the selling shareholders. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 525,000 common shares. The common shares are listed on the Nasdaq Global Market under the symbol “CNTG.”
Based in Rostock, Germany, Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. Centogene has developed a global proprietary rare disease platform, which includes epidemiologic, phenotypic and genetic data that reflects a global population and also a biobank of patients’ blood samples, which can aid the identification of patients and improve their pharmaceutical partners’ ability to bring orphan drugs to the market.
The Davis Polk corporate team included partner Leo Borchardt and associates Andrew Rowe, Serdar Inci and Saratu M. Kitchener. The tax team included partner Michael Mollerus and associate Tomislava Dragicevic. The intellectual property and technology transactions team included partner David R. Bauer and associate Jay Frankel. The executive compensation team included partner Edmond T. FitzGerald and associate Justin Alexander Kasprisin. Members of the Davis Polk team are based in the London and New York offices.